Endocrine Abstracts

Introduction: Agonist receptor-GLP1 (AR-GLP1) had demonstrated its utility in obese patients with diabetes type 2. Since August 2013 we have available in Spain a new AR-GLP1 with prandial action in a single daily dose, lixisenatide. There are different clinical trials that support its efficacy and security but the dates from real clinical practice are scarce.

Aim: To analyse the efficacy and security in real clinical practice for the treatment of diabetic type 2 patients with BMI ≥30 kg/m² in a 12 months period.

Materials and methods: Data from patients attending in an Endocrinology Unit from two Spanish centres were collected in a retrospective way (n=77). Initially, during 7 days patients received lixisenatide 10 μg in single dose and later, they received the maintenance dose of lixisenatide 20 μg. Primary endpoint was change in HbA1c from baseline. Body weight, adverse effects and others treatment for diabetes were collected. Available data were analysed with SPSS 20.

Results: 77 obese (32 males, age 58.02±12.5 years old) and type 2 diabetic patients (mean weight 94.53 kg, mean duration of diabetes 7.1 years, and mean HbA1c 9.01%). Data at 12 months of treatment were analysed. In this period, the HbA1c decreased −1.04±0.29% (P<0.001) and the body weight decreased 6.26±2.56 kg (P=0.01). Insulin was discontinued in 12.5% of the patients, mean initial dose 44 UI, mean final dose 29 UI, P=0.01. Mild transient gastrointestinal side effects were experimented by 8%. Three patients discontinued treatment (vomiting and refusing s.c. injection).

Conclusions: In our study, the efficacy of lixisenatide had been superior that reported in clinical trials in both aspects, HbA1c control and weight lost. In addition, this treatment had reduced the insulin requirements. Side effects are infrequent and mostly mild. More studies are necessary to support our results.